Clinical Trial Detail

NCT ID NCT02706626
Title Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Criterium, Inc.
Indications

non-small cell lung carcinoma

Therapies

Brigatinib

Age Groups: senior adult

Additional content available in CKB BOOST